Mirion Technologies, Inc. Q3 FY2026 earnings call

• Order Momentum: Total orders reached $386 million, an 85% increase including M&A. Core orders (ex-M&A) grew 62%. Nuclear power orders surged 105% ex-M&A. Large opportunity wins totaled $140 million.
• Backlog Conversion: Total backlog stands at $1.25 billion, up from $816 million a year ago. Approximately $735 million is expected to convert in Q4 2026 and full year 2027, de-risking near-term revenue.
• Nuclear Market Tailwinds: Three waves of demand are materializing: catch-up capital spending, life extensions/power upgrades (96% of US reactors approved for 20-year extensions), and digital transformation. The company has presence in >98% of world's nuclear reactors.
• AI and Cybersecurity Investment: Management is prioritizing significant investments in AI and cybersecurity over near-term margin targets. Year-to-date AI operating expenses exceeded $4 million, ahead of initial four-year budget plans. These investments are expected to drive long-term value through internal productivity and customer-facing product enhancements.
• Paragon Integration: While core Paragon margins are strong, a large-scale product development initiative in instrumentation and control has higher-than-anticipated spend and longer timelines for margin accretion. Management remains confident in achieving at least 25% year-over-year growth for Paragon.
• Capital Allocation: Management follows a rough 20-40-40 model: ~20% CapEx/organic growth, ~40% bolt-on M&A, and ~40% shareholder returns via share repurchases. Net leverage is expected to improve to ~2.6x by year-end.

Total revenue was $278 million, a 24.5% year-over-year increase. Organic revenue growth was 6.5%. Adjusted EBITDA was $65 million (23.3% margin).

Nuclear and Safety Segment: Revenue was $194 million, up 34% year-over-year (organic growth of 6.3%). Nuclear power organic revenue grew 14%, driven by the installed base and Small Modular Reactors (SMRs). Labs and Research declined, partially offset by Defense and Diversified growth. Paragon contributed significantly to this segment with 12% quarterly revenue growth and 22% year-to-date growth. Adjusted EBITDA was $49.8 million (25.7% margin), down from 28.1% last year due to Paragon integration dilution and legacy project adjustments.

Medical Segment: Revenue was $84 million, up 6.7% year-over-year (organic growth of 6.7%). Growth was driven by RTQA, nuclear medicine, and dosimetry services. Adjusted EBITDA was $31.7 million (37.8% margin), expanding 200 basis points year-over-year despite some one-time quality costs.

• Full-Year 2026 Revenue: Raised to 24-25% total growth (from 22-24%) and 7-8% organic growth (from 5-7%).
• Q4 2026 Organic Revenue: Expected to grow mid-to-high teens. Medical expected to grow mid-single-digits-plus; Nuclear and Safety expected to grow high-teens-plus.
• Adjusted EBITDA: Revised to $285-$292 million (down from prior high end) with margins of 24.7-25.2%. This reflects nuclear margin headwinds and lower-than-expected medical margin expansion.
• Adjusted Free Cash Flow: Raised to $170-$185 million (from $155-$175 million), representing 60-63% conversion of Adjusted EBITDA.
• Adjusted EPS: Tightened range to $0.50-$0.54 per share (from $0.48-$0.55).
• Net Leverage: Expected to improve to approximately 2.6 times by year-end midpoint, assuming no Q4 share repurchases or M&A.

• Margin Pressure: Nuclear and safety margins contracted due to legacy project adjustments within Paragon and headwinds in sensing/North America businesses. Medical margins expanded but were below internal expectations due to one-time quality costs.
• AI Investment Costs: Significant front-loading of AI and cybersecurity expenses may impact near-term profitability. Break-even timeline for these investments is not yet defined.
• Macroeconomic Factors: Medical sector growth has been tempered by external macro factors, though signs of recovery are present. Inflationary pressures on input costs are being managed but remain a risk.
• Regulatory and Funding Delays: Some large European orders (e.g., with EDF) are awaiting EU funding approval before appearing in backlog, creating timing uncertainty.
• SMR Market Volatility: While SMR activity is accelerating, the sector faces consolidation risks and competition among developers, potentially impacting long-term project timelines.

Q: Analyst asked about underlying nuclear margin trajectory post-headwinds and if 2027 would see moderation of these issues.

A: CEO stated that while Paragon’s core business is strong, a specific instrumentation/control product development initiative has higher-than-expected spend and longer timelines for margin accretion. Additionally, heavy investment in AI/cybersecurity and flat medical sector growth have led management to remove the aggressive 30-point near-term margin target to avoid distraction. However, they remain committed to annual margin expansion via operating leverage and self-help initiatives.

Q: Analyst inquired why now is the right time to lean into AI spending and where returns would appear in the P&L.

A: CEO explained AI spend covers three areas: data infrastructure, internal productivity, and customer-facing product development. Returns are expected to come from faster product releases and enhanced utility, but there is significant front-end loading of OPEX and CapEx. Management does not yet have a break-even date but views this as critical for long-term leadership and value creation.

Q: Analyst asked about capital allocation priorities between deleveraging and share repurchases as leverage drops.

A: CFO outlined a 20-40-40 model: ~20% to CapEx/organic growth, ~40% to bolt-on M&A, and ~40% to shareholders via buybacks. He emphasized that getting net leverage under 3.0x by year-end is an absolute priority, which may influence the pace of buybacks in Q4, though the company is happy with cash flow momentum.

Q: Analyst questioned the mix of order growth (multi-year vs. short-cycle) and how it translates to revenue visibility.

A: CFO noted a broad mix but highlighted that backlog conversion is happening nearer-term than previously assumed. Current year backlog conversion is up 18% and next year’s is up 26% compared to prior periods. This indicates that recent order momentum is driving near-term revenue recognition rather than just long-tail backlog build.

Q: Analyst asked about pricing power and inflation pass-through in the context of rising input costs.

A: CFO stated that procurement programs help manage inflation, with price-cost pressure being flattish recently. New large contracts include escalation clauses tied to indices. While medical side handles pricing more easily via book/bill dynamics, nuclear side faces challenges in passing costs through immediately. Overall, they feel they have a good handle on keeping up with inflation given supply-demand dynamics.